Point Biopharma shares sink 11% on study results; Lilly acquisition still up in air

Retrieved on: 2023-12-18 21:08:38

Tags for this article:

Click the tags to see associated articles and topics

Point Biopharma shares sink 11% on study results; Lilly acquisition still up in air. View article details on hiswai:

Excerpt

Results of a clinical trial for Point Biopharma's lead compound fell short of analysts' expectations, and that development is likely to pressure ...

Article found on: www.ibj.com